Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth

Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth

Summary

GBI Research, a leading business intelligence provider, has released its latest research report “Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth”. The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market and commanding greater value compared to the therapies already in the market. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

Despite recent patent expirations, including that of Advair Diskus (salmeterol/fluticasone propionate), a market leader, generic erosion in the COPD market may not be as pronounced as that observed in other indications. This is largely down to the difficulty in replicating a fixed-dose combination therapy and the associated device. Indeed, since the US patent expired in 2010, Advair Diskus has faced little generic competition.

Although the COPD market is characterized by low diagnosis rates, campaigns to increase awareness of the disease in both patients and physicians has resulted in steadily rising diagnosis of COPD. Therefore, this has also contributed to market growth throughout the forecast period.

Scope

- A disease introduction, which defines the disease, including symptoms, diagnosis and treatment.
- An analysis of the COPD marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, displayed as a heat map.
- A detailed analysis of the COPD pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The COPD clinical trial landscape is then analysed, with a particular emphasis on failure rates across phases as well as the trends in clinical trial size and duration and by mechanism of action.
- An in-depth forecasting model for the COPD market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies. This takes into account worst and best case scenarios for market uptake, costs and patent expirations.
- Strategic consolidations within the COPD indication are analyzed, which includes co-development and licensing agreements.
- An overview of the drivers and barriers for the COPD market is also included.

Reasons to buy

- Primarily, the report will allow clients to gain a strong understanding of the COPD indication, helping to identify and understand market opportunities and the emerging competitive environment. It will also allow you to:
- Understand the COPD pipeline and the factors which indicate that it is becoming more innovative as well as the key pipeline molecules that look set to have a big impact upon the COPD market.
- Observe detailed profiles for the promising pipeline products and gain insights into how they are likely to compete in the market, and what their main competitors will be.
- Follow the trends in COPD clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for COPD therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
- Observe the potential growth patterns expected for the COPD market over the forecast period, and identify which countries are expected to contribute most to this growth.

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Introduction 8
2.2 Symptoms 8
2.3 Etiology 8
2.4 Pathophysiology 9
2.5 Diagnosis 9
2.6 Assessment of Disease Severity 10
2.7 Treatment 10
2.7.1 Treatment Algorithm 12
3 Marketed Products 13
3.1 Product Profile 14
3.1.1 Spiriva – Boehringer Ingelheim Pharmaceuticals, Pfizer Inc. 14
3.1.2 Advair Diskus – GlaxoSmithKline 14
3.1.3 Symbicort – AstraZeneca (Co-promotion with Astellas Pharma Inc) 15
3.1.4 Combivent– Boehringer Ingelheim 16
3.1.5 Foradil – Novartis (Co-marketed by Novartis and Schering Corporation) 16
3.1.6 Arcapta/Onbrez Breezhaler – Novartis 17
3.1.7 Daliresp – Nycomed 18
3.1.8 Seebri Breezhaler – Novartis 19
3.1.9 Striverdi Respimat – Boehringer Ingelheim 19
3.1.10 Relvar/Breo – GlaxoSmithKline/Theravance 20
3.1.11 Heat Map – Marketed Products Overview 21
4 COPD Pipeline 23
4.1 Overview 23
4.2 Mechanisms of Action in the Pipeline 25
4.3 Clinical Trials 27
4.3.1 Failure Rate 27
4.3.2 Clinical Trial Duration 33
4.3.3 Clinical Trial Size 35
4.4 Promising Pipeline Molecules 38
4.4.1 Umeclidinium Bromide – GlaxoSmithKline 38
4.4.2 Umeclidinium Bromide + Vilanterol – GlaxoSmithKline/Theravance 38
4.4.3 Vilanterol Trifenatate – GlaxoSmithKline/Theravance 39
4.4.4 Olodaterol + tiotropium – Boehringer Ingelheim 39
4.4.5 TD-4208 – Theravance 40
4.4.6 QVA-149 – Novartis 40
4.4.7 Andolast (CR 2039) – Rottapharm | Madaus 41
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products 41
5 Market Forecast to 2019 47
5.1 Geographical Markets 47
5.1.1 Global Market 49
5.1.2 United States 51
5.1.3 Top Five Countries of Europe 54
5.1.4 Japan 58
5.2 Drivers and Barriers for the COPD Market 60
5.2.1 Drivers 60
5.2.2 Barriers 61
6 Strategic Consolidations 62
6.1 Major Co-development Deals 62
6.1.1 Galapagos Enters into Strategic Alliance with Roche 63
6.1.2 Five Prime Therapeutics Enters into Co-development Agreement with GlaxoSmithKline 63
6.1.3 Forest Labs Enters into Co-development Agreement with Nycomed 63
6.2 Major Licensing Deals 64
6.2.1 Orexo Enters into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica 67
6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma 68
6.2.3 Evotec Enters into Licensing Agreement with Zhejiang Conba Pharma for EVT 401 68
6.2.4 Halozyme Therapeutics Enters into Licensing Agreement with Intrexon 68
7 Appendix 69
7.1 All Pipeline Drugs by Phase 69
7.1.1 Discovery 69
7.1.2 Pre-clinical 70
7.1.3 Phase I 73
7.1.4 Phase II 74
7.1.5 Phase III 75
7.1.6 Filed 75
7.1.7 Undisclosed 76
7.1.8 Market Forecasts to 2019 76
7.1.9 The United States 76
7.1.10 The UK 77
7.1.11 France 77
7.1.12 Germany 77
7.1.13 Italy 78
7.1.14 Spain 78
7.1.15 Japan 78
7.2 Market Definition 79
7.3 Abbreviations 79
7.4 References 80
7.4.1 References for Pipeline Heat Map 85
7.4.2 References for Marketed Products Heat Map 86
7.5 Methodology 86
7.6 Coverage 87
7.7 Secondary Research 87
7.8 Therapeutic Landscape 87
7.9 Epidemiology-Based Forecasting 88
7.10 Market Size by Geography 89
7.11 Geographical Landscape 90
7.12 Pipeline Analysis 90
7.13 Competitive Landscape 90
7.13.1 Expert Panel Validation 90
7.14 Contact Us 90
7.15 Disclaimer 90

1.1 List of Tables
Table 1: COPD Market, Introduction, Disease Severity, 2012 10
Table 2: COPD Market, Introduction, Treatment Algorithm, 2012 12
Table 3: COPD Market, Global, Pipeline, Discovery, 2013 69
Table 4: COPD Market, Global, Pipeline, Pre-clinical, 2013 70
Table 5: COPD Market, Global, Pipeline, Phase I, 2013 73
Table 6: COPD Market, Global, Pipeline, Phase II, 2013 74
Table 7: COPD Market, Global, Pipeline, Phase III, 2013 75
Table 8: COPD Market, Global, Pipeline, Filed, 2013 75
Table 9: COPD Market, Global, Pipeline, Undisclosed, 2013 76
Table 10: COPD, Global, Market Forecast, 2012–2019 76
Table 11: COPD, US, Market Forecast, 2012–2019 76
Table 12: COPD, UK, Market Forecast, 2012–2019 77
Table 13: COPD, France, Market Forecast, 2012–2019 77
Table 14: COPD, Germany, Market Forecast, 2012–2019 77
Table 15: COPD, Italy, Market Forecast, 2012–2019 78
Table 16: COPD, Spain, Market Forecast, 2012–2019 78
Table 17: COPD, Japan, Market Forecast, 2012–2019 78

1.2 List of Figures
Figure 1: COPD Market, Global, Marketed Products, Heat Map, 2012 21
Figure 2: COPD Market, Global, Pipeline, 2012 24
Figure 3: COPD Market, Global, Pipeline by Mechanism of Action, 2012 25
Figure 4: COPD Market, Global, Clinical Trials, Failure Rate, 2012 28
Figure 5: COPD Market, Global, Clinical Trials, Failure Rates by 30
Figure 6: COPD Market, Global, Pipeline, Failure Rates by Mechanism of Action, Heat Map, 2012 31
Figure 7: COPD Market, Global, Pipeline, Clinical Trial Duration, 2012 33
Figure 8: COPD Market, Global, Pipeline, Clinical Trial Duration by Mechanism, 2012 34
Figure 9: COPD Market, Global, Pipeline, Clinical Trial Size, 2012 35
Figure 10: COPD Market, Global, Pipeline, Clinical Trial Size by Mechanism of Action, 2012 36
Figure 11: COPD Market, Global, Pipeline, Number of Clinical Trials per Drug, 2012 37
Figure 12: COPD Market, Global, Pipeline, Efficacy Heat Map, 2012 42
Figure 13: COPD Market, Global, Pipeline, Safety Heat Map, 2012 43
Figure 14: COPD Market, Global, Marketed Products, Heat Map, 2012 44
Figure 15: COPD Market, Global, Pipeline, Competitor Grid, 2012 46
Figure 16: COPD Market, Global, Treatment Patterns, 2012–2019 49
Figure 17: COPD Market, Global, Market Size ($m) 2012–2019 50
Figure 18: COPD Market, the US, Treatment Usage Patterns, Annual Cost of Treatment ($), 2012–2019 51
Figure 19: COPD Market, US, Market Size ($m), 2012–2019 52
Figure 20: COPD Market, Top Five EU Countries, Treatment Usage Patterns, 2012–2019 54
Figure 21: COPD Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019 55
Figure 22: COPD Market, Top Five EU Countries, Market Size ($m), 2012–2019 57
Figure 23: COPD Market, Japan, Treatment Usage Patterns, Annual Cost of Treatment ($), 2012–2019 58
Figure 24: COPD Market, Japan, Market Size ($m), 2012–2019 59
Figure 25: COPD Market, Global, Co-development Deals, 2006–2012 62
Figure 26: COPD Market, Global, Number and Aggregate Value of Co-development Deals by Year, 2006–2013 63
Figure 27: COPD Market, Global, Licensing Deals, 2006–2012 64
Figure 28: COPD Market, Global, Number and Aggregate Value of Licensing Deals by Year, 2006–2012 64
Figure 29: COPD Market, Global, Licensing Deals, 2006–2012 65
Figure 30: COPD Market, Global, Licensing Deals by Phase and Molecule Type and Aggregate Deal Value, 2006–2012 66
Figure 31: COPD Market, Global, Licensing Deals by Mechanism of Action, 2006–2012 67
Figure 32: COPD Market, Global, GBI Research Market Sizing Model 89